
PDA® Parenteral Drug Association

PARENTERAL PACKAGING CONFERENCE

15 YEARS OF ADVANCING PARENTERAL PACKAGING TECHNOLOGIES - WHAT WILL THE NEXT 15 YEARS BRING? pda.org/eu/parpack2025

25-26 MARCH 2025 CITY, COUNTRY: TBA

EXHIBITION: 25-26 MARCH 2025 TRAININGS: 27-28 MARCH 2025



WELCOME FROM THE CO-CHAIRS

Dear Colleague,

We would like to warmly invite you to submit a paper or poster abstract for presentation at the **15th edition** of the **PDA Parenteral Packaging Conference** which will take place on **25-26 March 2025.** The location will be announced soon.

Abstracts must be non-commercial in nature, describing new and innovative developments or work that significantly contributes to the body of knowledge relating to primary, secondary, and tertiary packaging of parenteral drugs and all related aspects as stated below.

The Scientific Program Planning Committee will review all proposals carefully and consider podium and poster contributions.

We look forward to receiving your topic proposal!

Sincerely, The Co-Chairs

Philippe Lauwers, *Termuo* Coralie Richard, *Eli Lilly and Company*



Philippe Lauwers, Terumo



Coralie Richard, *Eli Lilly and Company*

CALL FOR ABSTRACTS

TOPICS AREAS OF INTEREST WILL INCLUDE BUT



1. REGULATORY UPDATES

- Revisions from Global Pharmacopoeias and ISO Standards
- PDA Technical Reports
- FDA Guidance
- ICH Q3D-Elemental Impurities and their Application to Packaging Materials
- ICH Q3E-New Guideline in Development on Extractables and Leachables
- Managing Post-Approval Changes



2. DRUG - CONTAINER INTERACTIONS

- Silicone Layer Interactions
- Extractables and Leachables
- Delamination
- Incompatibilities, Degradation, and Other Formulation Considerations
- Fogging
- · Particles Origins and Characterization



3. DESIGN AND MATERIALS OF COMPONENTS AND CONTAINERS

- · Defects and their Categorization
- Surface Modified Materials
- Innovative Containers (e.g., ATMPs, Ophthalmics, and Ready-To-Use)
- · Considerations for Biocompatibility
- Alternative Materials (e.g., Applications, Benefits, and Limitations of Glass and Polymer Containers)
- · Large Volume Bags and Blow-Fill-Seal
- Rubber/Elastomer Components, Caps, Labels
- · Traceability and Anti-Counterfeiting
- Smart Packages: User Interactions and Drug Compliance
- Systems for Drug Administration (e.g., CSTDs)
- · Modeling, Robotics, and Automation
- Secondary and Tertiary Packaging
- Validation of Packaging Solutions and Packaging Performance



4. CONTAINER CLOSURE INTEGRITY (CCI)

- Product-Package Development
- Strategies for CCI Assurance (Container Closure System Qualification)
- API Storage Containers and Single-Use Equipment
- Influence of Pressure and Mechanical Stress During Shipping
- Relationship Between Visual Inspection and CCI Testing
- CCI Testing Across the Product Lifecycle and Different Test Methods
- CCI Phenomenology and Failure Mechanisms During Deep Cold Storage
- · Positive Controls
- Simulation and Modeling
- Product Release Specification vs. Internal Quality Criterion

SCIENTIFIC PROGRAM PLANNING COMMITTEE

Philippe Lauwers, Terumo

Coralie Richard, Eli Lilly and Company

Bettine Boltres, WEST

Madushini Dharmasena, U.S. FDA

Derek Duncan, LIGHTHOUSE Instruments

Ryan Forrey, BD

Matthew Hall, Corning

Bram Jongen, Datwyler

Arne Kloke, Alliance to Zero on behalf of SCHOTT Pharma

Miho Soma, Gilead

Folker Steden, SCHOTT Tubing

Jean-Sebastien Steffen, LONZA

Jessie Lindner, PDA

Falk Klar, PDA Europe

Stefanie Nebelin, PDA Europe

ARE NOT LIMITED TO THE FOLLOWING



5. PROCESSING AND PRODUCT DISTRIBUTION/STORAGE

- Sterilization and Decontamination (e.g., Vaporized Hydrogen Peroxide, Gamma Irradiation, Nitrogen Dioxide)
- Container Handling and Reduction of Breakage
- Fill-Finish Operations and Filling/Sealing Technologies and Controls
- Visual Inspection
- Approaches and Solutions for Cryogenic Storage
- Challenges in Shipping, Distribution, and Last-Mile Distribution
- Track and Trace: Serialization and Single Unit Identification
- Real-Time Digital Quality Control Across the Shelf Life
- Integrity and Statistical Risk Assessments
- Labeling
- Preparedness for the Next Pandemic



6. RE-THINKING PACKAGING FOR SUSTAINABILITY ADAPTION

- Impact of Planned Ban of Per- and Polyfluoroalkyl Substances (PFAS)
- Considerations and Solutions for Substances of Very High Concern (SVHCs)
- · Nitrosamines and Other Contaminations
- Product Carbon Footprint Calculations/Life Cycle Assessments of Parenteral Packaging, Devices, or Pharmaceutical Products (Cradle to Gate/Cradle)
- Recycling and Reuse Solutions for Primary/ Secondary Packaging, and Injection Devices
- Solutions to Reduce Product Carbon Footprints and Realize Net-Zero Products
- Circular Economy, Circular Packaging, and Circular Devices
- · Eco-Friendly Designs & Materials
- Disposal Practices Today and Tomorrow
- Water, Waste, and Energy Reduction Programs in Packaging Manufacturing and Fill-Finish
- Regulations: Hurdles and Incentives for the Transition to Net-Zero and Sustainable Products
- Reducing Hazardous Drug/Hazardous Medicinal Products Waste through Innovative Packaging (e.g., Multidose Vials, Vial Sizes Tailored to Doses)



7. BUSINESS CONTINUITY

- Package Development
- · Applications for New Package Solutions
- Machinability of Packaging
- · Safety Aspects
- Packaging Platform Technology
- · CDMO: Challenges, Selection, and Management
- Technology Transfer and Scale-Up
- Solving Supply Chain Issues (e.g., Single-Sourcing, Quality Issues, Lead Time)
- Business Development and Strategic Partnership
- Solving the Challenge of Cost Increase

Abstracts must be non-commercial in nature, describing new developments or work that significantly contributes to the body of knowledge relating to Parenteral Packaging.

DEADLINE: 06 SEPTEMBER 2024

All submitted abstracts will be reviewed by the Scientific Program Planning Committee for acceptance. PDA Europe will provide a complimentary registration per on-site podium presentation. Additional on-site presenters and on-site poster presenters are required to pay appropriate conference registration fees. Abstracts not selected for a podium presentation may be invited to join as a scientific poster contribution.

THE ONLINE PROCESS ASKS YOU TO PROVIDE THE FOLLOWING INFORMATION:

- PRESENTATION TITLE
- PRESENTER'S NAME AND CONTACT DETAILS
- PRESENTER'S BIOGRAPHY (APPROX. 100 WORDS)
- ADDITIONAL SPEAKERS (IF APPLICABLE)
- KEY OBJECTIVES OF TOPIC
- 2-3 PARAGRAPH ABSTRACT, SUMMARIZING THE TOPIC (MAX 300 WORDS)


Please click or scan the QR Code to submit your abstract.



https://bit.ly/4ceRyp

If you have any further questions, please do not hesitate to contact programs-europe@pda.org

TO EXHIBIT: PDA is seeking vendors who provide products/services in support of this conference. Space on-site is limited and is on a first-come, first-serve basis. To reserve your space, please contact Christopher Haertig at **expo-europe@pda.org**.



ALL POSTERS WILL BE PRINTED BY PDA AND DISPLAYED AS PART OF THE EXHIBITION.

Please send your file and poster title to Christopher Haertig at expo-europe@pda.org.
On-site poster presenters are required to pay a full conference registration fee.

JOIN OUR GUIDED POSTER WALK IN OUR EXHIBITION HALL AND GAIN MORE VISIBILITY

YOU WILL HAVE THE CHANCE TO ENGAGE WITH OUR POSTER AUDIENCE!

CONFERENCES AND EVENTS



FOR FURTHER INFORMATION FOLLOW US ONLINE

www.pda.org

2025	15 July 2024	
25-26 MAR 2025	PDA Parenteral Packaging Conference 2025	ТВА
20-21 MAY 2025	PDA Good Digital Manufacturing Conference 2025	Basel, Switzerland
22-23 MAY 2025	PDA Good Aseptic Manufacturing Conference 2025	Basel, Switzerland
24-25 JUNE 2025	PDA Virus Conference 2025	Gothenburg, Sweden
26-27 JUNE 2025	PDA Advanced Therapy Medicinal Products Conference 2025	Gothenburg, Sweden
SEP 2025	PDA BioManufacturing Conference 2025	Italy
21-22 OCT 2025	PDA Universe of Pre-Filled Syringes and Injection Device Conference 2025	Vienna, Austria
NOV 2025	PDA Visual Inspection Workshop 2025	Berlin, Germany